No profile data available.
Exelixis, Inc. (EXEL) is a healthcare company in the additional cancer treatment drugs industry, based in Alameda, United States, with about 1,077 full-time employees.
It reported revenue of $2.32 billion for fiscal year 2025, up 7.0% from fiscal year 2024, and net income of $782.57 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $628.69 million, up 10.6% from a year before. United States was its largest region in fiscal year 2025, with 92% of revenue. Its market capitalization was $14.83 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Exelixis reported $2.32 billion in revenue for fiscal year 2025, up 7.0% from $2.17 billion in fiscal year 2024. In Q2 2026 revenue was $628.69 million.
United States: 92% of revenue by region in fiscal year 2025, followed by Europe (7%).
$14.83 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Merck & Co., Inc. (MRK), Bristol-Myers Squibb Company (BMY), Revolution Medicines, Inc. (RVMD), Summit Therapeutics Inc. (SMMT).